Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lenalidomide, subcutaneous bortezomib, and dexamethasone in newly diagnosed multiple myeloma
2013-005008-32Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Cancer Trials Ireland. Primary endpoints: Overall response rate after 4 cycles of induction therapy and Best overall response to induction therapy. Started Apr 2014; status: completed.
02
Drugs
lenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-005008-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005008-32.